Lataa...
Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers
HER2, a member of the Erythroblastosis Protein B/Human Epidermal Growth Factor Receptor (ErbB/HER) family of receptor tyrosine kinase, is overexpressed in 20~30% of human breast cancers. Trastuzumab, a HER2-targeted therapeutic monoclonal antibody, was developed to interfere with the homodimerizatio...
Tallennettuna:
| Julkaisussa: | Antibodies (Basel) |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7931022/ https://ncbi.nlm.nih.gov/pubmed/33557368 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/antib10010007 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|